Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy

Background/Aim. Dysregulation of fatty acid (FA) metabolism is recognized as a component of malignant trans-formation in many cancers, including breast cancer (BC), and is often related to disease progression and prognosis. Adjuvant endocrine BC therapy using aromatase inhibitors may also influence...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Krstić Predrag, Vučić Vesna, Paunović Marija, Petrović Snjezana, Nedović Nikola, Kostić Sanja, Arsić Aleksandra
Formato:	article
Lenguaje:	EN SR
Publicado:	Military Health Department, Ministry of Defance, Serbia 2021
Materias:	aromatase inhibitors antineoplastic agents breast neoplasms fatty acids postmenopause women Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/deeb5ff497e44caf8ed544c52e65bbf1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:deeb5ff497e44caf8ed544c52e65bbf1
record_format	dspace
spelling	oai:doaj.org-article:deeb5ff497e44caf8ed544c52e65bbf12021-12-01T13:00:25ZSimilar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy0042-84502406-072010.2298/VSP200124032Khttps://doaj.org/article/deeb5ff497e44caf8ed544c52e65bbf12021-01-01T00:00:00Zhttp://www.doiserbia.nb.rs/img/doi/0042-8450/2021/0042-84502000032K.pdfhttps://doaj.org/toc/0042-8450https://doaj.org/toc/2406-0720Background/Aim. Dysregulation of fatty acid (FA) metabolism is recognized as a component of malignant trans-formation in many cancers, including breast cancer (BC), and is often related to disease progression and prognosis. Adjuvant endocrine BC therapy using aromatase inhibitors may also influence FA metabolism. Thus, the aim of our study was to compare plasma total lipids FA status in newly diagnosed postmenopausal patients with BC and in postmenopausal women with BC receiving aromatase inhibitors at least 2 years after completing chemotherapy with healthy women. Methods. The study included 17 newly diagnosed postmenopausal BC patients (ND group) and 21 postmenopausal women with BC receiving aromatase inhibitor therapy 2 years after ending chemotherapy (AI group), while a total of 15 apparently healthy women without a family history of BC, comparable in age and body mass index, served as a control group. Results. In both patient groups, we found significantly lower levels of vaccenic acid (18:1n-7), alpha-linolenic acid (18:3n-3), gamma-linolenic acid (GLA, 18:3n-6), and docosapentae-noic acid (22:5n-3), and a significantly higher level of di-homo-gamma-linolenic (20:3n-6), when compared with the control group. On the other hand, a significantly lower level of stearic acid (18:0) was observed only in AI patients, while the level of linoleic acid (18:2n-6) was significantly higher in ND women than in the control group. Reduced estimated activities of D6 and D5 desaturases were found in both patient groups than in the control group. Conclusion. Our results indicate that FA profiles of plasma lipids of the newly diagnosed, untreated BC patients are very similar to those of cured BC patients who underwent all sessions of chemotherapy and received aromatase inhibitors for at least two years. Additionally, according to our results, their FA profiles markedly differ from those of healthy women. Therefore, supplementation with omega-3 FA and GLA could have beneficial effects in these patients, and further studies should address the potential clinical benefits of the supplementation.Krstić PredragVučić VesnaPaunović MarijaPetrović SnjezanaNedović NikolaKostić SanjaArsić AleksandraMilitary Health Department, Ministry of Defance, Serbiaarticlearomatase inhibitorsantineoplastic agentsbreast neoplasmsfatty acidspostmenopausewomenMedicine (General)R5-920ENSRVojnosanitetski Pregled, Vol 78, Iss 11, Pp 1140-1145 (2021)
institution	DOAJ
collection	DOAJ
language	EN SR
topic	aromatase inhibitors antineoplastic agents breast neoplasms fatty acids postmenopause women Medicine (General) R5-920
spellingShingle	aromatase inhibitors antineoplastic agents breast neoplasms fatty acids postmenopause women Medicine (General) R5-920 Krstić Predrag Vučić Vesna Paunović Marija Petrović Snjezana Nedović Nikola Kostić Sanja Arsić Aleksandra Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy
description	Background/Aim. Dysregulation of fatty acid (FA) metabolism is recognized as a component of malignant trans-formation in many cancers, including breast cancer (BC), and is often related to disease progression and prognosis. Adjuvant endocrine BC therapy using aromatase inhibitors may also influence FA metabolism. Thus, the aim of our study was to compare plasma total lipids FA status in newly diagnosed postmenopausal patients with BC and in postmenopausal women with BC receiving aromatase inhibitors at least 2 years after completing chemotherapy with healthy women. Methods. The study included 17 newly diagnosed postmenopausal BC patients (ND group) and 21 postmenopausal women with BC receiving aromatase inhibitor therapy 2 years after ending chemotherapy (AI group), while a total of 15 apparently healthy women without a family history of BC, comparable in age and body mass index, served as a control group. Results. In both patient groups, we found significantly lower levels of vaccenic acid (18:1n-7), alpha-linolenic acid (18:3n-3), gamma-linolenic acid (GLA, 18:3n-6), and docosapentae-noic acid (22:5n-3), and a significantly higher level of di-homo-gamma-linolenic (20:3n-6), when compared with the control group. On the other hand, a significantly lower level of stearic acid (18:0) was observed only in AI patients, while the level of linoleic acid (18:2n-6) was significantly higher in ND women than in the control group. Reduced estimated activities of D6 and D5 desaturases were found in both patient groups than in the control group. Conclusion. Our results indicate that FA profiles of plasma lipids of the newly diagnosed, untreated BC patients are very similar to those of cured BC patients who underwent all sessions of chemotherapy and received aromatase inhibitors for at least two years. Additionally, according to our results, their FA profiles markedly differ from those of healthy women. Therefore, supplementation with omega-3 FA and GLA could have beneficial effects in these patients, and further studies should address the potential clinical benefits of the supplementation.
format	article
author	Krstić Predrag Vučić Vesna Paunović Marija Petrović Snjezana Nedović Nikola Kostić Sanja Arsić Aleksandra
author_facet	Krstić Predrag Vučić Vesna Paunović Marija Petrović Snjezana Nedović Nikola Kostić Sanja Arsić Aleksandra
author_sort	Krstić Predrag
title	Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy
title_short	Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy
title_full	Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy
title_fullStr	Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy
title_full_unstemmed	Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy
title_sort	similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy
publisher	Military Health Department, Ministry of Defance, Serbia
publishDate	2021
url	https://doaj.org/article/deeb5ff497e44caf8ed544c52e65bbf1
work_keys_str_mv	AT krsticpredrag similarfattyacidstatusofplasmalipidsinpostmenopausalwomennewlydiagnosedwithbreastcancerandthosereceivingaromataseinhibitortherapy AT vucicvesna similarfattyacidstatusofplasmalipidsinpostmenopausalwomennewlydiagnosedwithbreastcancerandthosereceivingaromataseinhibitortherapy AT paunovicmarija similarfattyacidstatusofplasmalipidsinpostmenopausalwomennewlydiagnosedwithbreastcancerandthosereceivingaromataseinhibitortherapy AT petrovicsnjezana similarfattyacidstatusofplasmalipidsinpostmenopausalwomennewlydiagnosedwithbreastcancerandthosereceivingaromataseinhibitortherapy AT nedovicnikola similarfattyacidstatusofplasmalipidsinpostmenopausalwomennewlydiagnosedwithbreastcancerandthosereceivingaromataseinhibitortherapy AT kosticsanja similarfattyacidstatusofplasmalipidsinpostmenopausalwomennewlydiagnosedwithbreastcancerandthosereceivingaromataseinhibitortherapy AT arsicaleksandra similarfattyacidstatusofplasmalipidsinpostmenopausalwomennewlydiagnosedwithbreastcancerandthosereceivingaromataseinhibitortherapy
_version_	1718405205928706048

Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy

Ejemplares similares